Format

Send to

Choose Destination
Mol Ther. 2017 Apr 5;25(4):989-1002. doi: 10.1016/j.ymthe.2017.01.010. Epub 2017 Feb 16.

Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.

Author information

1
Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA.
2
Department of Biological and Environmental Engineering, Cornell University, Ithaca, NY 14853 USA.
3
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
4
Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA.
5
College of Agriculture and Life Sciences, Cornell University, Ithaca, NY 14853, USA.
6
Department of Microbiology and Immunology, Cornell University College of Veterinary Medicine, Ithaca, NY 14853, USA.
7
Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY 14853, USA. Electronic address: dap43@cornell.edu.

Abstract

Recombinant, Escherichia coli-derived outer membrane vesicles (rOMVs), which display heterologous protein subunits, have potential as a vaccine adjuvant platform. One drawback to rOMVs is their lipopolysaccharide (LPS) content, limiting their translatability to the clinic due to potential adverse effects. Here, we explore a unique rOMV construct with structurally remodeled lipids containing only the lipid IVa portion of LPS, which does not stimulate human TLR4. The rOMVs are derived from a genetically engineered B strain of E. coli, ClearColi, which produces lipid IVa, and which was further engineered in our laboratory to hypervesiculate and make rOMVs. We report that rOMVs derived from this lipid IVa strain have substantially attenuated pyrogenicity yet retain high levels of immunogenicity, promote dendritic cell maturation, and generate a balanced Th1/Th2 humoral response. Additionally, an influenza A virus matrix 2 protein-based antigen displayed on these rOMVs resulted in 100% survival against a lethal challenge with two influenza A virus strains (H1N1 and H3N2) in mice with different genetic backgrounds (BALB/c, C57BL/6, and DBA/2J). Additionally, a two-log reduction of lung viral titer was achieved in a ferret model of influenza infection with human pandemic H1N1. The rOMVs reported herein represent a potentially safe and simple subunit vaccine delivery platform.

KEYWORDS:

M2e; adjuvants; endotoxin; influenza; outer membrane vesicles; subunit vaccine delivery

PMID:
28215994
PMCID:
PMC5383554
DOI:
10.1016/j.ymthe.2017.01.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center